Trial Profile
Phase II trial of adjuvant TC (docetaxel/cyclophosphamide) plus trastuzumab in HER2 [human epidermal growth factor receptor 2]-positive early stage breast cancer patients
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs Docetaxel (Primary) ; Cyclophosphamide; Trastuzumab
- Indications Breast cancer
- Focus Therapeutic Use
- 20 May 2014 Status changed from active, no longer recruiting to completed, as per ClinicalTrials.gov record.
- 13 Apr 2010 Planned number of patients changed from 260 to 493 as reported by ClinicalTrials.gov.
- 13 Apr 2010 Planned end date (1 Feb 2011) added as reported by ClinicalTrials.gov.